Buscar
Mostrando ítems 1-10 de 372
Isoniazid Preventive Therapy in Contacts of Multidrug-resistant Tuberculosis.
(American Thoracic Society, 2020)
RATIONALE: The World Health Organization recommends the use of isoniazid alone or in combination with rifapentine to treat latent tuberculosis infection. The recent rise of drug-resistant tuberculosis has complicated the ...
Isoniazid preventive therapy and risk for resistant tuberculosis
(Centers for Disease Control and Prevention (CDC), 2006)
In the context of tuberculosis (TB) resurgence, isoniazid preventive therapy (IPT) is increasingly promoted, but concerns about the risk for development of isoniazid-resistant tuberculosis may hinder its widespread ...
The need for randomised controlled trials of isoniazid monoresistant tuberculosis treatment
(Elsevier, 2017)
We read with interest the meta-analysis by Medea Gegia and colleagues that reviewed treatment outcomes of isoniazid-resistant tuberculosis when treated with first-line drugs. The authors reviewed all studies published ...
Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin-Mono-Resistant Pulmonary Tuberculosis in Lima, Peru
(Public Library of Science, 2016)
BACKGROUND: Isoniazid and rifampicin are the two most efficacious first-line agents for tuberculosis (TB) treatment. We assessed the prevalence of isoniazid and rifampicin mono-resistance, associated risk factors, and the ...
Isoniazid: A Review of Characteristics, Properties and Analytical Methods
(2017-07-04)
Isoniazid is a synthetic antimicrobial and one of the most important first-line drugs used in the treatment of tuberculosis. Since it was introduced in the therapy in 1952, the drug remains at the front line of the ...
Characterization of ndh gene of isoniazid resistant and susceptible Mycobacterium tuberculosis isolates from Brazil
(Instituto Oswaldo Cruz, Ministério da Saúde, 2007-02-01)
Resistance in Mycobacterium tuberculosis to isoniazid (INH) is caused by mutations in the catalase-peroxidase gene (katG) , and within the inhA promoter and/or in structural gene. A small percentage (~ 10%) of INH-resistant ...
Characterization of ndh gene of isoniazid resistant and susceptible Mycobacterium tuberculosis isolates from Brazil
(Instituto Oswaldo Cruz, Ministério da Saúde, 2007-02-01)
Resistance in Mycobacterium tuberculosis to isoniazid (INH) is caused by mutations in the catalase-peroxidase gene (katG) , and within the inhA promoter and/or in structural gene. A small percentage (~ 10%) of INH-resistant ...
Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis
The molecular basis for isoniazid resistance in Mycobacterium tuberculosis is complex. Putative isoniazid resistance mutations have been identified in katG, ahpC, inhA, kasA, and ndh. However, small sample sizes and related ...
Is the efflux pump inhibitor Verapamil a potential booster for isoniazid against Mycobacterium tuberculosis?
(Univ Sao Paulo, Conjunto Quimicas, 2020-01-01)
The membrane-based efflux pump systems are recognized to have an important role in pathogenicity and drug resistance in Mycobacterium tuberculosis by the extrusion of toxic substrates and drugs from the inner bacillus. ...
Treatment outcomes for isoniazid-monoresistant tuberculosis in Peru, 2012-2014
(Public Library of Science, 2018)
Background: Resistance to isoniazid is the most common form of drug-resistance in tuberculosis. However only a tiny proportion of TB patients in the world have access to isoniazid drug susceptibility testing—the widely ...